Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte is targeting $3 billion to $4 billion in non-JAKAFI sales by 2030, up from roughly $2 billion currently, supported by a broader late-stage pipeline and potential 15%–20% annual growth from 2030 to 2035. The company is preparing for JAKAFI’s loss of exclusivity after 2029, with JAKAFI XR formulary coverage expected to reach 70%–80% by year-end. Converting 10%–30% of patients to the extended-release version could preserve nearly $750 million in transition-period sales. Key pipeline programs are advancing across hematology, oncology and dermatology, including CALR antibody 989, KRAS G12D inhibitor 734, TGF-beta/PD-1 bispecific 890 and povorcitinib; Incyte is also expanding through the acquisition of Vega Therapeutics’ von Willebrand disease candidate latarcibart.

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over the past year, citing proof-of-concept data for its CALR antibody 989 in myelofibrosis and essential thrombocythemia, its KRAS G12D inhibitor in pancreatic cancer, and its TGF-beta-by-PD-1 program in colorectal cancer. He also pointed to phase III data for povorcitinib, which is under FDA review, and the acquisition of Vega Therapeutics and its von Willebrand disease candidate latarcibart.

Meury said Incyte’s core business excluding JAKAFI is annualizing at roughly $2 billion in sales. The company aims to increase that figure to $3 billion to $4 billion by 2030. If its pipeline programs are successfully developed and launched, he said Incyte has the potential to grow at a 15% to 20% compound annual rate from 2030 through 2035.

Meury said the company expects extended-release JAKAFI XR formulary coverage to approach 70% to 80% by year-end. According to Meury, major pharmacy benefit managers and health plans have placed XR on formulary at parity with immediate-release JAKAFI and at a price acceptable to both Incyte and payers.

Incyte has projected that 10% to 30% of JAKAFI patients could convert to XR before loss of exclusivity. At the midpoint of that range, Meury said the conversion could preserve nearly $750 million in sales during the transition. He characterized XR as a bridge rather than a primary driver of Incyte’s long-term value. President and Global Head of R&D Pablo Cagnoni said 989 is already in pivotal development for second-line essential thrombocythemia, while a second-line myelofibrosis study is being implemented. The company plans to provide more details on the myelofibrosis trial design during its next earnings call. For frontline myelofibrosis, Incyte expects to present data at the American Society of Hematology meeting from a cohort in which roughly two-thirds of patients received 989 monotherapy and one-third received 989 with ruxolitinib. Cagnoni said the data will help determine the design of a planned frontline trial expected to begin in early 2027. The company is also discussing potential endpoints with the FDA. Cagnoni said Incyte believes measures including hemoglobin, platelets, blasts and spleen size could support a composite endpoint that better reflects disease modification. The company continues to have a “constructive dialogue” with the agency, he said, but retains a path to approve 989 using existing endpoint.